Destabilization of steroid receptors by heat shock protein 90-binding drugs: A ligand-independent approach to hormonal therapy of breast cancer

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 2076-2084

  Bagatell, Rochelle ^a   Khan, Omar ^a   Paine Murrieta, Gillian ^b   Taylor, Charles W ^b   Akinaga, Shiro ^c   Whitesell, Luke ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; CHAPERONE; ESTROGEN RECEPTOR; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HORMONE BINDING PROTEIN; KF 58333; LIGAND; PROGESTERONE RECEPTOR; RADICICOL; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HORMONE BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TREATMENT OUTCOME; TUMOR XENOGRAFT; UTERUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BREAST NEOPLASMS; CELL DIVISION; ESTROGENS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LIGANDS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; QUINONES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; TIME FACTORS; TUMOR CELLS, CULTURED; UTERUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034777916     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Tamoxifen in the treatment of breast cancer
2. Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy
3. Abnormal estrogen receptor in clinical breast cancer
4. Comparative analyses of mechanistic differences among antiestrogens
5. Tamoxifen: The herald of a new era of preventive therapeutics
6. Steroid receptors and their associated proteins
7. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent
8. Crystal structure of an hsp90-geldanamycin complex: Targeting of a protein chaperone by an anti-tumor agent
9. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
10. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation
11. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin
12. Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) in rats
13. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(l) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex
14. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells
15. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin
16. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent
17. Human tumor models in the severe combined immune deficient (scid) mouse
18. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90 binding agents
19. Endocrine therapy of advanced breast cancer
20. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
21. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
22. Reduced levels of hsp90 compromise steroid receptor action in vivo
23. Distinct functions of the 90-kDa heat shock protein (hsp90) in oestrogen and mineralocorticosteroid receptor activity: Effects of hsp90 deletion mutants
24. Control of estrogen receptor ligand binding by Hsp90
25. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
26. The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors
27. Hsp90's secrets unfold: New insights from structural and functional studies
28. ICI 182, 780 (Faslodex): Development of a novel "pure" antiestrogen
29. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling
30. Role of the heat shock response and molecular chaperones in oncogenesis and cell death
31. Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher concentrations
32. Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence
33. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives
34. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
35. Synthesis and evaluation of geldanamycin-estradiol hybrids, bioorganic, and medicinal chemistry
36. Activation of the Src/p21ras/Erk pathway by progesterone receptor via crosstalk with estrogen receptor
37. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, Tamoxifen-resistant breast cancer cells
38. Hypothesis. Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals
39. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
40. Geldanamycin selectively destabilizes and conformationally alters mutated p53
41. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo
42. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice
43. Development and characterization of a Tamoxifen-resistant breast carcinoma xenograft